For the quarter ending 2025-09-30, BEIGF made $1,412,284,000 in revenue. $124,841,000 in net income. Net profit margin of 8.84%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 1,412,284,000 | 1,315,300,000 | 1,117,279,000 | 924,390,500 |
| Cost of sales - product | - | - | 165,002,000 | 142,747,500 |
| Cost of sales - product-Product | 196,510,000 | 164,606,000 | - | - |
| Gross profit | 1,215,774,000 | 1,150,694,000 | 952,277,000 | 796,990,500 |
| Research and development | 523,662,000 | 524,896,000 | 481,887,000 | 501,325,000 |
| Selling, general and administrative | 528,998,000 | 537,913,000 | 459,288,000 | 466,052,000 |
| Total operating expenses | 1,052,660,000 | 1,062,809,000 | 941,175,000 | 967,377,000 |
| Income (loss) from operations | 163,114,000 | 87,885,000 | 11,102,000 | -170,386,500 |
| Interest income, net | 3,029,000 | 3,497,000 | 5,848,000 | 12,397,666.667 |
| Other (expense) income, net | -18,979,000 | 8,167,000 | 3,950,000 | -5,986,000 |
| Income (loss) before income taxes | 147,164,000 | 99,549,000 | 20,900,000 | -164,388,500 |
| Income tax expense | 22,323,000 | 5,229,000 | 19,630,000 | 37,127,000 |
| Net income (loss) | 124,841,000 | 94,320,000 | 1,270,000 | -201,515,500 |
| Basic (in dollars per share) | 0.09 | 0.07 | 0 | -0.145 |
| Diluted (in dollars per share) | 0.08 | 0.06 | 0 | -0.145 |
| Weighted-average shares outstanding diluted (in shares) | 1,488,750,354 | 1,463,277,401 | 1,445,253,219 | -684,543,823.5 |
| Weighted-average shares outstandingbasic (in shares) | 1,432,801,699 | 1,408,166,754 | 1,390,052,966 | -684,543,823.5 |
BeOne Medicines Ltd. (BEIGF)
BeOne Medicines Ltd. (BEIGF)